Scientists probe immune cells to unravel a rare leukemia
NCT ID NCT03280888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood cells from people with chronic myelomonocytic leukemia (CMML) to learn more about how the disease works. Researchers will study specific immune cells, including monocytes and immature granulocytes, to understand why they don't develop normally. The goal is to find new clues about CMML that could lead to better treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could uncover new targets for future treatments for CMML.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nice
RECRUITINGNice, 06000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a Two-Drug combo tame a rare blood cancer?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Three-Drug cocktail aims to tame transplant complications in blood cancer patients